ToolsCalculators
International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)
Integrates clinical, biochemical, and genetic factors to stratify survival in CLL.
International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)
Age >65 years
Binet stage B/C (or Rai stage I-IV)
IGHV unmutated
del(17p) and/or TP53 mutation
Serum beta-2-microglobulin >3.5 mg/L
Result0 points
Low-risk group; reported 5-year overall survival ~93.2%.
- Risk group
- Low
- 5-year overall survival
- 93.2%
When to use
- Stratifying expected survival at diagnosis of chronic lymphocytic leukemia using clinical, laboratory, and genetic data.
Formula
Points: age >65 = 1; Binet B/C (or Rai I-IV) = 1; IGHV unmutated = 2; del(17p)/TP53 mutation = 4; beta2-microglobulin >3.5 mg/L = 2. Total 0-10: Low 0-1, Intermediate 2-3, High 4-6, Very high 7-10.
Pearls and pitfalls
- del(17p)/TP53 mutation carries the heaviest weight, reflecting its dominant impact on chemoimmunotherapy resistance.